Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376159 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL3179881 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708630 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL7287734 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL1448119 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL949983 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708628 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL26604823 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL13164545 | 0.95 | ABCB1 (0.47) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL29548192 | 0.93 | MCL1 (0.50) | ABCB1AGTR2KLK7MCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2280970-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009132986-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | disclosed |
| EP-1012180-B1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGUES | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-12-01 | — | — | EP | disclosed |
| US-6143715-A | FOR TREATING AND PREVENTION OF HEPATITIS C VIURS INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-11-07 | — | — | US | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995009859-A1 | BOROPEPTIDE INHIBITORS OF THROMBIN WHICH CONTAIN A SUBSTITUTED PYRROLIDINE RING | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HSD11B1, HSD17B1, HSD17B11 | ABCB1 285/4885AGTR2 959/4885KLK7 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.